ZSWIM8 Knockout cell line (HeLa)

CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.

ZSWIM8 (zinc finger SWIM-type containing 8) encodes a component of the Cul3-RING ubiquitin ligase complex that functions as a ubiquitin-like ligase-substrate adaptor. ZSWIM8 contributes to protein ubiquitination and proteolysis involved in protein catabolic processes. Through its role in ubiquitin-mediated regulation, ZSWIM8 participates in the control of macromolecule metabolism and cellular protein turnover.

The HeLa cell line is a globally utilized immortal human cervical cancer cell line, historically distinguished as the first aneuploid, continuously cultured human cell line established in 1951. Originally isolated from an epitheloid cervix carcinoma of a 31-year-old Black female (with a later updated diagnosis of adenocarcinoma), HeLa cells are characterized by their rapid proliferation and exceptionally stable growth profiles. Serving as a foundational model in cancer research, gene editing (e.g., CRISPR), and drug screening, this line also plays a critical role in virology due to its high susceptibility to Poliovirus type I and adenovirus type 3. Because of its robust growth advantage, HeLa has been frequently identified as a prominent cross-contaminant in numerous other cell lines, and therefore must be strictly managed and handled under laboratory containment level 2.

Comprehensive quality control includes STR authentication, sterility testing (bacteria and fungi), and mycoplasma screening to ensure purity and performance. Genotype is confirmed by two rounds of PCR and Sanger sequencing, and complete validation reports are provided for make-to-order products.